The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, ...

Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.

Moderna stock was a highflier in early pandemic days as sales of its coronavirus vaccine soared.

Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new ...

iShares Biotechnology ETF earns a reiterated hold rating as it consolidates near all-time highs with balanced risk/reward. IBB’s valuation is fair at a 19x P/E and low 3% EPS growth, resulting in an ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of 2020 and 2021 and an anticipated stock recovery in 2024 failed to materialise.